Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You bought his shares.
Got that right brother
Eco
I'm a bowler. Only use a 15.lb ball these days because of technology and expect the same from the RVVTF CEO!
I'm not blowing smoke up someone's proverbial and I sure am not in league with anyone, but I've watched naysayers dispute Ecomike's positive claims on a stock that seemed dead, and low and behold, if I'd had money to invest in that stock I would have enjoyed hefty gains.
For a newbie who has nothing left right now but hope in what seems like a shitty situation I'll trust the words of someone with a track record of being right when everyone else was wrong.
P. S. I hope Giovanni and Gatorca didn't top themselves today.
LOL now you pivot to the orphan drug status and shrooms? You have no shame.
Let me guess you saw this all coming?
Yes, and that was our hope with RLFTF too. But the big pharma buyout never happened. It's just a pipe dream IMO. But then again, stranger things have happened. There are investors on RLFTF that lost hundreds of thousands of dollars. And I'm sure that there are some here are sitting on those type of losses too. However, the insiders always win, and Michael Frank still gets his big fat salaries and bonuses. It is what it is.
LMAO, today's reading comprehension panic disabled, $RVVTF selling market took itself to the cleaners in a panic selloff today being led to the culling by fake news interpretations of the earlier US PR this morning.
Later today this came out:
https://newsytrends.com/2023/03/20/revive-therapeutics-ltd-cse-rvv-otcmkts-rvvtf-reverses-off-52-week-lows-as-fda-adjusts-endpoints-in-bucillamine-trials-more-on-rvv-psilocybin-clinical-study/
Revive Therapeutics Ltd (OTCMKTS: RVVTF) is a biotech sleeper that hit new 52 week lows on Monday after the FDA adjusted the endpoints of its Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19. The Company is still committed to advancing the clinical and commercial development of Bucillamine and decided that in the best interest of the Study to preserve and not compromise the integrity of the Study and keep the blinded data intact to support a potential FDA approval in the future. Revive has a lot going on besides this; the Company was granted orphan drug designation for cannabidiol in the treatment of autoimmune hepatitis by the FDA and has entered into a clinical trial agreement with The Trustees of Indiana University to develop and manage a clinical study entitled, “Use of Cannabidiol as an adjunct therapy for difficult to treat autoimmune hepatitis.”
Revive Therapeutics made a legendary run up the charts during 2020 culminating in a run to over $0.70 per share in the US. Now the stock has reversed off $0.0296 lows in the US after over reacting on the Bucillamine update.
Revive has a lot going on; the Company is evaluating psilocybin in a Phase 1/2 clinical study for methamphetamine use disorder via a research collaboration with the University of Wisconsin-Madison, developing a novel psilocybin oral thin film strip through a feasibility agreement with LTS Lohmann Therapie-Systeme AG, a leader in pharmaceutical oral thin films as well as developing a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform under its research collaboration with North Carolina State University. We will be updating on Revive Therapeutics when more details emerge ...
Revice hit new lows on Monday after the Company announced an update from the FDA Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties in patients with mild to moderate COVID-19. On March 8th, 2023, the Company received the Type C meeting written responses from the FDA to obtain agreement on the proposed protocol endpoints for the Company’s Study. The FDA recommended that the Company’s proposed primary symptom-based endpoint should cover the evaluation of time to sustained recovery assessed over an appropriate duration, evidence of subjects experiencing resolution of COVID-19 related symptoms and the element of sustained symptom resolution.
After a further in-depth review and analysis of the FDA recommendations with members of the Company’s clinical trial team, including its statistician, regulatory affairs, medical affairs, and clinical research advisors, the Company has decided that in the best interest of the Study to preserve and not compromise the integrity of the Study and keep the blinded data intact to support a potential FDA approval in the future. As a result, the Company is committed to advancing the clinical and commercial development of Bucillamine and plans to pursue the following activities:
Continue discussions with the FDA on a pathway for future potential regulatory approval under the current Study’s objectives, which the FDA and DSMB continue to support;
Work with the Study’s current participating clinical sites and potential new clinical sites to develop a defined recruitment plan that prioritizes subjects recognized to be at higher risk for developing severe COVID-19 to achieve the Study’s objectives;
Determine potential opportunities of unblinding additional data related to the Study for evaluation to support future discussions with the FDA, and further studies for Long COVID or COVID symptom-related conditions, which the FDA provided advice to pursue, and various infectious and respiratory disorders;
Develop reformulation strategies of Bucillamine to expand on its potential therapeutic utility targeting rare disorders that may come with regulatory incentives awarded by the FDA, such as orphan drug (i.e. ischemia-reperfusion injury, cystinuria), fast track, and breakthrough therapy designations; and
Secure alliances with strategic partners, including pharmaceutical companies, to achieve Bucillamine’s full commercial potential.
"Currently trading at a $22 million market valuation Revive Therapeutics os is 320,008,751 with 315,580,417 shares in the public float. "
Bullish head and shoulders 3 year pattern is a buy. And there is 100% rally gap over head to cover from the morning low.
Ironically, I think big pharma is the only hope. If they partner/purchase buc it would most likely get fast-tracked. They managed to get their stuff approved in almost a rubber stamp manner.
That's been my key learning with all this. The little guy doesnt have much of a chance.
I can think of something that is more unethical and immoral. I'm sure i don't need to tell YOU, and i'm sure your many followers know what that is.
Interesting that hedge fund backed, BP backed shorts are so motivated to push a fake news scam and fraud narrative about $RVVTF and the CEO while the US FDA, US Justice Department, FBI and SEC have made no such claims.
Pushing a fake news scammy narrative to profit off of folks that invested to save lives is unethical and immoral.
And just like RLFTF, the CEO (Michael Frank) and other fat cat insiders still get their fat salaries and bonus checks. No loss for them. They still did just fine in the pandemic.
As predicted, RVVTF followed the same path as RLFTF. Both foreign tiny biotechs, and the FDA doesn't give them the attention they give USA Big Pharma. I saw this coming, and I feel bad for the longs. I've also never had any faith in this CEO's competency level. He's always been too hooked on shrooms. At least the O/S is not in the stratosphere like it is with RLFTF, so I don't think an R/S is on the horizon just yet. But clearly investor patience has worn thin, COVID is winding down, and the big money has already been made for most with this pandemic. JMHO.
This sucks bad. We all got taken to the woodshed by this CEO three years. Now is going to be 3 years for this to even go above a dime. I had hope with this stock. When I saw ECO pumping the stock. I know it's was all over. God luck CW.
A lot of lawsuit talk on the reddit board. Even Biomedical Trader blamed management this morning as to the reason for this disaster.
If you are right about us being scammed, CEO Michael Frank should go into hiding. Seriously.
I fear the sentiment is as it is over on the Reddit board and MF will drag this out as long as possible to collect his six figure salary.
As was stated over there we were told they would unblind the data regardless whether or not the FDA approved the end points. Now he claims they will not unblind the data.
This has all the markings of a scam at this point. Unfortunately I’ve been a part of these before on the OTC with fraudulent CEO’s milking it to the last drop
Good luck on your increased investment. If I had powder to bet with I believe one half of my brain would have talked me in to buying more on the dip because of A.
As it is I continue to hold and hope that A will be the reason that an entity with way more clout is already planning its move to take Bucillamine to the finish line.
Me too. Broke it down to 2 bets.
A. on the science, with good promise and
B. on the company, a long shot.
I bought today, but not because of B.
A part of me wishes it was well and truly over, even with the massive loss entailed. At least then one could move on with a tried but failed mindset instead of more holding and hoping. Selling would equally suck because of FOMO.
Fress sure did make a smart move back in December '20.
Your not alone CW,all us longs are feeling the pain.Lets hope we can get some back.
I'm disappointed today more than most. I couldn't even follow the stock after the initial selloff. No point in selling here. I just hope to make some money back in time and maybe close the year at a dime. Who knows? Holding but not expecting greatness anymore. I lost a lot today on paper. Like others selling at $.70 would have made too much sense. Ugh.
Yes I had just under 300,000 shares at a average of 20 cents.
No chance. He took investor mon eye at .15
All sounds good uncle Mike. You have ba$$s. I will hold and ride your coattails.
Thanks again for you insight.
Be interesting to see if the CEO bought the dip today and files a form 4
We will find out on Wednesday.
I have been down $700,000 on paper, on one stock.
You get use to the wild swings after a while on OTC.
Being diversified helps a lot, Never put all the eggs in one basket.
There are no, no risk investments. One of the 10 largest US banks failed this month.
Poof just like, it was dead. Silicone Valley Bank.
Risk reward wise, this is a great one. Today's news does not change my mind, it only reminds me how many wolves and sheep there are gaming the stock market, just like claims made that the FDA games the drug winners and losers, there are games played to milk retail of their shares..
I never sell shares at loss. That is just my style. I also never buy shares in company I am not willing to buy more on dips.
L-2 on $RVVTF was all screwed up this morning and short MMs (convertible MMs even) were all over it, and it was hard to tell what was going on with most OTC stocks this morning. It took over 2 hours for most of the L-2 OTC stock data mess to clear up.
I started buying more RVVTF shares about 30 minutes ago.
There is a huge chart gap overhead formed at the open today, that needs to fill, back up to at least .068 range
No one should have sold the bottom today, that is a rookie mistake.
Bid support seems to be strong at the .037 Fib range now.
The news left a lot of future rally doors open for solid upside. Some body, BP(?) Hedge Funds(?) wanted this stock way down and got it down 70% off the price RVVTF raised 4.3 Million dollars at, namely at .10/share
We can speculate later on what the 2nd half of the PR says that is bullish, lots of bullish options listed.
https://www.proactiveinvestors.com/companies/news/1009552/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-bucillamine-in-treatment-of-covid-19-1009552.html
Be interesting to see if the CEO bought the dip today and files a form 4.
My opinions on RVVTF have not changed. In fact it is a better buy now than before, who would not buy at 70% off the price they just raised 4.3 Million dollars at? or 95% off the 2 year high?
The FDA trial is still underway.
Google dollar cost averaging folks.
I have never owned any shares in this security just seen it going down since last October from .30 to where it is now
You should never dump when news causes a dump. Remember there are lots of holders with millions of shares. Should at least move up from these levels over the next few days with more clarity. Let the dump die out. They have one than one item in the pipeline.. Let the price recoup let your emotions subside before jumping out. Calm down and wait for a better price before selling. That’s my opinion.
Your down 51,000.00 dollars?
Cannacord is probably in the process of renting a bunch of nooses right now.
Yep. So said for all who took the pump
Imagine those investors who bought the offering at a premium
govprs, BTW unfortunately your .05 prediction was wrong! LOL
Dont know if it will help but BMT on reddit said he is down 117,000......misery loves company.
wise man, there is still a lot of value in this stock once all the dust settles from this disappointment.
Hotel Delta.....Im going to hold as I need .20 to break even, down 51,000 right now.
Rubberneck2 I feel your pain, this is money that I had no business throwing away especially on a penny stock. I never learn my lesson but now that I am such deep shit with money issues, I am done with investing. These days it's all short sellers and day traders who profit. Long term investors are getting screwed big time. Since the company is still afloat, maybe just maybe something good will happen for us. At this point it doesn't pay to sell. I'll just wait it out until the end of the year. GLTU and all who thought this shitty little company would make us some serious money.
Rubber.....yep,I was up nice when this shot up before could of sold but was
greedy (as usual) and blew it......I did the same with another little sub penny
stock I bought about the same time as RVVTF.....bought in at 0.0004 it ran to 4 cents
and I was up 15,000 on a 250 investment..did I sell....NOOOOO and now its back
down to 0.0003.....this stuff isnt for me,I will hold and see what happens,hope it
maybe get back to .15 - .20 and I can break even at some point.
Well said. Penny stocks are always a risk as all of you know. Ups and downs are normal. I'm still hanging on, won't sell, no reason too I don't need the loss until the end of the year. I still have hope I can at least recover my loss by the end of the year.
Noble words in the face of a shitty result It's only. Within 7 months this stock put me in a position to pay off my mortgage and all other debt too. Greed prevented me from doing so. And here we are, with no one to blame but ourselves.
Lessons learned.
Sooooo. No MF monogrammed sweatpants now?
HAHAHAHAHAHAHA!!!!!
I have no one to blame but myself,really thought they had something and as I said
im ride or die.....well im dead.
Followers
|
337
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36642
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |